The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: Defining a consensus terminology

Paola Cinque, Igor J. Koralnik, David B. Clifford

Research output: Contribution to journalArticle

Abstract

There is a need for consistent definition of human immunodeficiency virus (HIV)-associated cases of progressive multifocal leukoencephalopathy (PML), especially following the profound disease changes that have resulted from the use of highly active antiretroviral therapy (HAART). According to the criteria used for diagnosis, PML cases should be either referred to as "histologyconfirmed," with evidence of JC virus (JCV) infection in brain, "laboratoryconfirmed," with detection of JCV DNA in cerebrospinal fluid (CSF), or "possible," in the presence of typical clinical and radiological picture, but no demonstration of JCV infection. Disease outcome should be defined by the evidence or lack of evidence of disease activity, rather than using survival or other variables. Disease activity should be based on clinical (scored neurological examination), radiological (magnetic resonance imaging), and virological (JCV DNA levels in CSF) indicators, to be assessed regularly, e.g., every 3 months until evidence of disease arrest or death. Furthermore, parallel assessments of other HIV-associated manifestations, including CD4+ cell counts and viral load, are required. A standard patient classification would be helpful for clinical management of PML patients, for their inclusion in clinical studies, and also will increase our current knowledge of PML and its evolution in relation with HAART.

Original languageEnglish
Pages (from-to)88-92
Number of pages5
JournalJournal of NeuroVirology
Volume9
Issue numberSUPPL. 1
Publication statusPublished - 2003

Fingerprint

Progressive Multifocal Leukoencephalopathy
JC Virus
Terminology
HIV
Highly Active Antiretroviral Therapy
Virus Diseases
Cerebrospinal Fluid
DNA
Neurologic Examination
CD4 Lymphocyte Count
Viral Load
Magnetic Resonance Imaging
Survival
Brain

Keywords

  • Diagnosis
  • HAART
  • JC virus
  • Progressive multifocal leukoencephalopathy

ASJC Scopus subject areas

  • Virology
  • Clinical Neurology

Cite this

The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy : Defining a consensus terminology. / Cinque, Paola; Koralnik, Igor J.; Clifford, David B.

In: Journal of NeuroVirology, Vol. 9, No. SUPPL. 1, 2003, p. 88-92.

Research output: Contribution to journalArticle

@article{9d0ce70fbbf548d5ba3f714a490ca557,
title = "The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: Defining a consensus terminology",
abstract = "There is a need for consistent definition of human immunodeficiency virus (HIV)-associated cases of progressive multifocal leukoencephalopathy (PML), especially following the profound disease changes that have resulted from the use of highly active antiretroviral therapy (HAART). According to the criteria used for diagnosis, PML cases should be either referred to as {"}histologyconfirmed,{"} with evidence of JC virus (JCV) infection in brain, {"}laboratoryconfirmed,{"} with detection of JCV DNA in cerebrospinal fluid (CSF), or {"}possible,{"} in the presence of typical clinical and radiological picture, but no demonstration of JCV infection. Disease outcome should be defined by the evidence or lack of evidence of disease activity, rather than using survival or other variables. Disease activity should be based on clinical (scored neurological examination), radiological (magnetic resonance imaging), and virological (JCV DNA levels in CSF) indicators, to be assessed regularly, e.g., every 3 months until evidence of disease arrest or death. Furthermore, parallel assessments of other HIV-associated manifestations, including CD4+ cell counts and viral load, are required. A standard patient classification would be helpful for clinical management of PML patients, for their inclusion in clinical studies, and also will increase our current knowledge of PML and its evolution in relation with HAART.",
keywords = "Diagnosis, HAART, JC virus, Progressive multifocal leukoencephalopathy",
author = "Paola Cinque and Koralnik, {Igor J.} and Clifford, {David B.}",
year = "2003",
language = "English",
volume = "9",
pages = "88--92",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy

T2 - Defining a consensus terminology

AU - Cinque, Paola

AU - Koralnik, Igor J.

AU - Clifford, David B.

PY - 2003

Y1 - 2003

N2 - There is a need for consistent definition of human immunodeficiency virus (HIV)-associated cases of progressive multifocal leukoencephalopathy (PML), especially following the profound disease changes that have resulted from the use of highly active antiretroviral therapy (HAART). According to the criteria used for diagnosis, PML cases should be either referred to as "histologyconfirmed," with evidence of JC virus (JCV) infection in brain, "laboratoryconfirmed," with detection of JCV DNA in cerebrospinal fluid (CSF), or "possible," in the presence of typical clinical and radiological picture, but no demonstration of JCV infection. Disease outcome should be defined by the evidence or lack of evidence of disease activity, rather than using survival or other variables. Disease activity should be based on clinical (scored neurological examination), radiological (magnetic resonance imaging), and virological (JCV DNA levels in CSF) indicators, to be assessed regularly, e.g., every 3 months until evidence of disease arrest or death. Furthermore, parallel assessments of other HIV-associated manifestations, including CD4+ cell counts and viral load, are required. A standard patient classification would be helpful for clinical management of PML patients, for their inclusion in clinical studies, and also will increase our current knowledge of PML and its evolution in relation with HAART.

AB - There is a need for consistent definition of human immunodeficiency virus (HIV)-associated cases of progressive multifocal leukoencephalopathy (PML), especially following the profound disease changes that have resulted from the use of highly active antiretroviral therapy (HAART). According to the criteria used for diagnosis, PML cases should be either referred to as "histologyconfirmed," with evidence of JC virus (JCV) infection in brain, "laboratoryconfirmed," with detection of JCV DNA in cerebrospinal fluid (CSF), or "possible," in the presence of typical clinical and radiological picture, but no demonstration of JCV infection. Disease outcome should be defined by the evidence or lack of evidence of disease activity, rather than using survival or other variables. Disease activity should be based on clinical (scored neurological examination), radiological (magnetic resonance imaging), and virological (JCV DNA levels in CSF) indicators, to be assessed regularly, e.g., every 3 months until evidence of disease arrest or death. Furthermore, parallel assessments of other HIV-associated manifestations, including CD4+ cell counts and viral load, are required. A standard patient classification would be helpful for clinical management of PML patients, for their inclusion in clinical studies, and also will increase our current knowledge of PML and its evolution in relation with HAART.

KW - Diagnosis

KW - HAART

KW - JC virus

KW - Progressive multifocal leukoencephalopathy

UR - http://www.scopus.com/inward/record.url?scp=0038363319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038363319&partnerID=8YFLogxK

M3 - Article

C2 - 12709878

AN - SCOPUS:0038363319

VL - 9

SP - 88

EP - 92

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - SUPPL. 1

ER -